N. Bail

发表

Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors

Y. Merrouche, M. Alakl, J. Guastalla, 2004, Cancer Chemotherapy and Pharmacology.

Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies

A. Bousseau, V. Blanc, J. Lambert, 2013 .

Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation

M. Aapro, M. Marty, A. Iliadis, 2004, Cancer Chemotherapy and Pharmacology.

Phase I II M ulticenter R andomized T rial o f O xaliplatin Added t o C hronomodulated F luorouracil-Leu covorin a s First-Line T reatment o f M etastatic C olorectal C ancer

S. Giacchetti, C. Focan, P. Chollet, 2000 .

Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult

J. Verweij, M. Glabbeke, H. Mouridsen, 1994 .

A phase I study of Taxotere (RP 56976 NSC 628503) administered as a one hour intravenous infusion on a weekly basis

M. Piccart-Gebhart, J. Sculier, E. Tomiak, 1991 .

Leucovorin a nd F luorouracil W ith o r W ithout O xaliplatin as F irst-Line T reatment i n A dvanced C olorectal C ancer

C. Wilson, C. Boni, A. Figer, 2000 .

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

C. Wilson, C. Boni, F. D. De Braud, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

F. Lévi, S. Giacchetti, C. Focan, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.

M. Marty, J. Extra, R. Bruno, 1993, Cancer research.

Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.

D. Kerr, D. Bissett, P. Wilson, 1993, Cancer research.

A phase II study of taxotere in patients with advanced head and neck cancer

M. Piccart, J. Wanders, J. Verweij, 1993 .

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.

C. Tournigand, E. Raymond, A. Gramont, 1997, European journal of cancer.

Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck

M. Piccart, J. Wanders, J. Verweij, 1994 .

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.

C. Sternberg, N. Pavlidis, S. Kaye, 1994, British Journal of Cancer.

Taxotere in the treatment of advanced colorectal carcinoma

J. Wanders, C. Sternberg, N. Pavlidis, 1993 .

Taxotere in advanced malignant melanoma: A fase-II trial of the eortc early clinical trials group

M. Piccart, S. Aamdal, R. Paridaens, 1993 .

Phase II study with taxotere(RP56976) in advanced soft tissue sarcomas of the adult

J. Verweij, M. Glabbeke, H. Mouridsen, 1993 .